<DOC>
	<DOCNO>NCT01615198</DOCNO>
	<brief_summary>The purpose study access efficacy safety LCZ696 compare olmesartan elderly Asian patient treatment hypertension .</brief_summary>
	<brief_title>Efficacy Safety LCZ696 Comparison Olmesartan Elderly Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Patients must give write informed consent assessment perform Patients essential hypertension , untreated currently take antihypertensive therapy must mean sit systolic blood pressure ≥ 150 mmHg &lt; 180 mmHg Patients must able communicate comply study requirement demonstrate good medication compliance Exclusion criterion : Patients severe hypertension ( msDBP ≥ 110 mmHg and/or msSBP ≥180 mmHg ) . Patients history angioedema , drugrelated otherwise Patients history evidence secondary form hypertension Transient ischemic cerebral attack ( TIA ) 12 month prior Visit 1 history stroke History myocardial infarction , coronary bypass surgery percutaneous coronary intervention ( PCI ) 12 month prior Visit 1 . Current angina pectoris require medication ( patient stable dose oral topical nitrate ) . Patients Type 1 Type 2 diabetes mellitus well control stable dose antidiabetic medication Patients previous current diagnosis heart failure ( NYHA Class IIIV ) . Patients clinically significant valvular heart disease time screen Women childbearing potential , use adequate birth control methods Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hypertension , blood pressure , LCZ696 , dual inhibitor , neprilysin , NEP inhibition , vasopeptidase , ARNi , angiotensin receptor</keyword>
</DOC>